SLC5A2 and diabetes mellitus: Regarding the renoprotective effects of pharmacotherapy, in addition to blood pressure optimization with the conventional use of renin-angiotensin system (RAS) blockers, such as an angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been recently found to improve cardiovascular and renal outcomes in patients with CKD, irrespective of diabetes status [4–6].